TAIWAN-PLUS
30.8.2021 17:40:11 CEST | Business Wire | Press release
Taiwan Plus (Taiwan+), the first English-language international streaming platform of Taiwan, was unveiled by Vice President Lai Ching-te, Legislative Speaker You Si-kun, Culture Minister Lee Yung-te, Central News Agency (CNA) Chairman Liu Ka-shiang, Taiwan+ CEO Joanne Tsai, and H.E. Ambassador Jasmine E. Huggins of Embassy of Saint Christopher and Nevis at the National Taiwan Museum in Taipei on Aug. 30.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005461/en/
Targeting English-speaking audience, Taiwan+ consists of media professionals from the U.S., the U.K, Canada, France, and Australia, as well as local industry professionals, who work collaboratively to deliver the latest news about Taiwan, international affairs, and covers a wide range of topics. The platform also sources stories from Taiwan’s public and private media organizations.
Golden Melody-award winning singer Sanpuy Katatepan Mavaliyw opened the event with a music performance. Held with COVID-19 prevention measures in place, the event was joined by representatives including Izumi Hiroyasu from Japan, Jordan Reeves from Canada, Andrew Wylegala and Don Shapiro from the U.S., and Henry Chang and Giuseppe Izzo from Europe.
H.E. Ambassador Jasmine E. Huggins of Embassy of Saint Christopher and Nevis in Taiwan said the international video platform is expected to connect Taiwan with the world.
President Tsai Ing-wen expressed her pleasure to join the launch of Taiwan+ with a video message, saying “Taiwan+ is an exciting new initiative to tell Taiwan’s story. Generations of Taiwanese fought to transform this country into a vibrant democracy that protects freedom of speech and expression.”
Premier Su Tseng-chang wished the platform success. He stressed that Taiwan is a democratic and free country guided by the rule of law, and cares about universal values of human rights, freedom of speech and diversity, noting that this is why many countries are willing to make friends and do business with Taiwan.
Vice President Lai said, “I hope that the platform can be the starting point from which the world learns about what Taiwanese people think and want, what Taiwan is doing, and what we can contribute to the world.”
Legislative Speaker You noted that, with China’s intimidation and political oppression against Taiwan, the establishment of Taiwan+ allows Taiwan to tell its stories to the world through its voices.
Taiwan+, a project commissioned by the Ministry of Culture to the CNA, marks an important milestone in the country’s history of mass media, Minister Lee said. He expressed his gratitude to legislators and professionals for making this happen.
“I hope to make this platform a form of expansion, connection, and infinite possibilities, just like how Taiwan incorporates ethnic, cultural and linguistic diversity, and introduce Taiwan to the world through dynamic storytelling and news,” said Tsai, a senior media professional with over 25 years of experience in international media outlets, such as NBC/CNBC, National Geographic, and Fox International Channels.
The content of Taiwan+ can be played on the Taiwan Plus app or viewed on its website and social media platforms, such as Facebook, YouTube, Twitter, and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005461/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom